Neko Health: Geographic Expansion

The leadership read

Neko Health's New York launch commits the company to a regulatory, clinical, and operational architecture it has never had to build before. Operating proprietary diagnostic hardware across US states means navigating FDA device classification, state medical practice acts, and insurance-adjacent liability exposure simultaneously, none of which have direct equivalents in the UK or Swedish frameworks the company matured in. The $700M raise is sized for this: standing up physical scanning infrastructure in multiple US cities within a single calendar year is a capital-intensive, operationally sequenced problem, and the funding signals that the board has accepted the full cost of doing it at pace rather than testing a single market slowly. This is one of 12 geographic expansion signals we have tracked across sectors in the last 90 days. The relevant comparable is Deepgram establishing an APAC headquarters in Singapore with state-backed investment, and VinFast's simultaneous US and Southeast Asia push: both cases where a company with proven home-market product crossed into a jurisdiction demanding materially different regulatory and commercial infrastructure at the same time as physical footprint. Neko's case is more acute because its product is the facility, not software that can be deployed remotely. Companies reaching this stage of cross-jurisdictional physical expansion in healthtech face concentrated demand for regulatory operations leadership fluent in both FDA and state-level clinical frameworks, commercial and partnerships leadership able to negotiate real-estate and clinical-staffing structures across multiple US metros at speed, and product leadership capable of adapting AI-driven clinical workflows to US liability standards without degrading the member experience that is driving 75% rebooking rates.